Practice parameter: The care of the patient with amyotrophic lateral sclerosis (an evidence-based review)

Muscle and Nerve

Volumn 22, Issue 8, 1999, Pages 1104-1118

  Miller, R G ^a   Rosenberg, J A ^a   Gelinas, D F ^a   Mitsumoto, H ^a   Newman, D ^a   Sufit, R ^a   Borasio, G D ^a   Bradley, W G ^a   Bromberg, M B ^a   Brooks, B R ^a   Kasarskis, E J ^a   Munsat, T L ^a   Oppenheimer, E A ^a  

^a AMERICAN ACADEMY OF NEUROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ATROPINE; GLYCOPYRRONIUM BROMIDE; OPIATE; SCOPOLAMINE; TRIHEXYPHENIDYL;

AMYOTROPHIC LATERAL SCLEROSIS; ASPIRATION PNEUMONIA; DYSPHAGIA; DYSPNEA; HYPERSALIVATION; PALLIATIVE THERAPY; PATIENT CARE; PRIORITY JOURNAL; RESPIRATORY FAILURE; RESPIRATORY FUNCTION; REVIEW; SYMPTOMATOLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; HUMANS; QUALITY OF LIFE;

EID: 0032787694     PISSN: 0148639X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4598(199908)22:8<1104::AID-MUS15>3.0.CO;2-2     Document Type: Review

References (112)

1. Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on the treatment of amyotrophic lateral sclerosis with riluzole. Neurology 1997;49: 657-659. (Class I)
2. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases, El Escorial "Clinical Limits of Amyotrophic Lateral Sclerosis" Workshop Contributors. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124(suppl):96-107. (Class III)
3. Lind SE, Good MD, Seidel S, Csordas T, Good BJ. Telling the diagnosis in cancer. J Clin Oncol 1989;7:583-589. (Class III)
4. Damian D, Tattersall MHN. Letters to patients: improving communication in cancer care. Lancet 1991;338:923-925. (Class I)
5. Tattersall MHN, Butow PN, Griffin A, Dunn SM. The take-home message: patients prefer consultation audiotapes to summary letters. J Clin Oncol 1994;12:1305-1311. (Class I)
6. Doyle D. Breaking bad news. J R Soc Med 1996;89:590-591. (Class III)
7. Okamura H, Uchitomi Y, Sasako M, Eguchi K, Kakizoe T. Guidelines for telling the truth to cancer patients. J Clin Oncol 1998;2:1-4. (Class III)
8. Post SG, Whitehouse PJ. Fairhill guidelines on the ethics of the care of people with Alzheimer's disease: a clinical summary. Center for Biomedical Ethics, Case Western Reserve University and the Alzheimer's Association. J Am Geriatr Soc 1995;43:1423-1429. (Class III)
9. Davies E, Hopkins A. Good practice in the management of adults with malignant cerebral glioma: clinical guidelines. Working group. Br J Neurosurg 1997;11:318-330. (Class III)
10. Girgis A, Sanson-Fisher RW. Breaking bad news: consensus guidelines for medical practitioners. J Clin Oncol 1995;13: 2449-2456. (Class III)
11. Ptacek JT, Eberhardt TL. Breaking bad news: a review of the literature. JAMA 1996;276:496-502. (Class III)
12. Blackball LJ, Murphy ST, Frank G, Michel V, Azen S. Ethnicity and attitudes toward patient autonomy. JAMA 1995; 274:820-825. (Class III)
13. Charchaflie RJ, Fernandez LB, Perec CJ, Gonzalez E, Marzi A. Functional studies of the parotid and pancreas glands in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1974;37:863-867. (Class III)
14. Goode RL, Smith RA. The surgical management of sialorrhea. Laryngoscope 1970;80:1078-1089. (Class III)
15. Blasco PA, Stansbury JCK. Glycopyrrolate treatment of chronic drooling. Arch Pediatr Adolesc Med 1996;150: 932-935. (Class III)
16. Stern LM. Preliminary study of glycopyrrolate in the management of drooling. J Paediatr Child Health 1997;33:52-54. (Class III)
17. Camp-Bruno JA, Winsberg BG, Green-Parsons AR, Abrams JP. Efficacy of benztropine therapy for drooling. Dev Med Child Neurol 1989;31:309-319. (Class I)
18. Reddihough D, Johnson H, Staples M, Hudson I, Exarchos H. Use of trihexyphenidol hydrochloride to control drooling of children with cerebral palsy. Dev Med Child Neurol 1990;32:985-989. (Class III)
19. Brodtkorb E, Wyzocka-Bakowska MM, Lillevold PE, Sandvik L, Saunte C, Hestnes A. Transdermal scopolamine in drooling. J Ment Def Res 1988;32:233-237. (Class I)
20. Lewis DW, Fontana C, Mehallick LK, Everett Y. Transdermal scopolamine for reductions in drooling in developmentally delayed children. Dev Med Child Neurol 1994;36:484-486. (Class I)
21. Talmi YP, Finkelstein Y, Zohar Y, Laurian N. Reduction of salivary flow with scopoderm TTS. Ann Otol Rhinol Laryngol 1988;97:128-130. (Class III)
22. Dworkin JP, Nadal JC. Nonsurgical treatment of drooling in a patient with closed head injury and severe dysarthria. Dysphagia 1991;6:40-49. (Class III)
23. Newell AR, Orser R, Hunt M. The control of oral secretions in bulbar ALS/MND. J Neurol Sci 1996;139(suppl):43-44. (Class III)
24. Bach JR. Mechanical insufflation-exsufflation: comparison of peak expiratory flows with manually assisted and unassisted coughing techniques. Chest 1993;104:1553-1562. (Class III)
25. Bach JR, Smith WH, Michaels J, et al. Airway secretion clearance by mechanical exsufflation for postpoliomyelitis ventilator assisted individuals. Arch Phys Med Rehabil 1993;74: 170-177. (Class III)
26. Robinson ACR, Khoury GG, Robinson PM. Role of irradiation in the suppression of parotid secretions. J Laryngol Otol 1989;103:594-595. (Class III)
27. Janzen VD, Rae R, Hudson AJ. Otolaryngologic manifestations of amyotrophic lateral sclerosis. J Otolaryngol 1988;17: 41-42. (Class III)
28. Poeck K. Pathologisches lachen und weinen bei bulbrer myatrophischer lateralsklerose. Deutsche Med Wochenschr 1996;94:310-314. (Class III)
29. Schiffer RB, Cash J, Herndon RM. Treatment of emotional lability with low-dosage tricyclic antidepressants. Psychosomatics 1983;24:1094-1096. (Class III)
30. Caroscio JT, Cohen JA, Gudesblatt M. Amitriptyline in amyotropic lateral sclerosis. N Engl J Med 1985;313:1478. Letter. (Class III)
31. Gallagher JP. Pathologic laughter and crying in ALS: a search for their origin. Acta Neurol Scand 1989;80:114-117. (Class III)
32. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985;312:1480-1482. (Class I)
33. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol 1996;19:532-535. (Class III)
34. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. The nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 1996;63:130-137. (Class III)
35. Slowie LA, Paige MS, Antel JP. Nutritional considerations in the management of patients with amyotrophic lateral sclerosis (ALS). J Am Diet Assoc 1983;83:44-47. (Class III)
36. Martin BJ, Corlew MM, Wood H, et al. The association of swallowing dysfunction and aspiration pneumonia. Dysphagia 1994;9:1-6. (Class II)
37. Schmidt J, Holas M, Halvorson K, Reding M. Videofluoroscopic evidence of aspiration predicts pneumonia and death but not dehydration following stroke. Dysphagia 1994;9: 7-11. (Class III)
38. Wilcox F, Liss JM, Siegel GM. Interjudge agreement in video-fluoroscopic studies of swallowing. J Speech Hear Res 1996; 39:144-152. (Class III)
39. Mathus-Vliegen LMH, Louwerse LS, Merkus MP, Tytgat GNS, Vianney de Jong JMP. Percutaneous endoscopie gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc 1994;40: 463-469. (Class II)
40. Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopie gastrostomy and enterai nutrition in amyotrophic lateral sclerosis. Neurology 1995; 242:695-698. (Class II)
41. Llaneza PP, Menendez AM, Roberts R, Dunn GD. Percutaneous endoscopic gastrostomy: clinical experience and follow-up. South Med J 1988;81:321-324. (Class III)
42. Mighell AJ, Carton ATM, Boobis LH, Stassen LFA. Acceptance and perception of percutaneous endoscopie gastrostomy by patients with upper digestive tract cancer. Br J Oral Maxillofac Surg 1995;33:19-22. (Class III)
43. Park RH, Allison MC, Lang J, et al. Randomised comparison of percutaneous endoscopie gastrostomy and nasogastric tube feeding in patients with persisting neurological dysphagia. BMJ 1992;304:1406-1409. (Class I)
44. Akpunonu BE, Mutgi AB, Roberts C, Khuder SA, Federman DJ, Lee L. Modified barium swallow does not affect how often PEGs are placed after stroke. J Clin Gastroenterol 1997;24:74-78. (Class III)
45. Leighton SEJ, Burton MJ, Lund WS, Cochrane GM. Swallowing in motor neuron disease. J R Soc Med 1994;87:801-805. (Class III)
46. The role of percutaneous endoscopie gastrostomy in enterai feeding. Guidelines for clinical application. Gastrointest Endosc 1988;34(suppl 3):35S-36S. (Class III)
47. Sherman MS, Paz HL. Review of respiratory care of the patient with amyotrophic lateral sclerosis. Respiration 1994;61: 61-67. (Class III)
48. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. Neurology 1998;50:66-72. (Class I)
49. Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med 1997;15:357-365. (Class III)
50. DiSario JA, Foutch PG, Sanowski RA. Poor results with percutaneous endoscopie jejunostomy. Gastrointest Endosc 1990;36:257-260. (Class III)
51. Hassett JM, Sunby C, Flint LM. No elimination of aspiration pneumonia in neurologically diabled patients with feeding gastrostomy. Surg Gynecol Obstet 1988;167:383-388. (Class II)
52. Jarnagin WR, Duh Q, Mulvihill SJ, Ridge JA, Schrock TR, Way LW. The efficacy and limitations of percutaneous endoscopic gastrostomy. Arch Surg 1992;127:261-264. (Class III)
53. Kadakia SC, Sullivan HO, Starnes E. Percutaneous endoscopic gastrostomy or jejunostomy and the incidence of aspiration in 79 patients. AmJ Surg 1992:164:114-118. (Class III)
54. Patel PH, Thomas E. Risk factors for pneumonia after percutaneous endoscopie gastrostomy. Clin Gastroenterol 1990; 12:389-392. (Class III)
55. Cogen R, Weinryb J. Aspiration pneumonia in nursing home patients fed via gastrostomy tubes. AmJ Gastroenterol 1989; 84:1509-1512. (Class III)
56. Light VL, Slezak FA, Porter JA, Gerson LW, McCord G. Predictive factors for early mortality after percutaneous endoscopic gastrostomy. Gastrointest Endosc 1995;42:330-335. (Class III)
57. Sartori S, Trevisani L, Tassinari D, et al. Prevention of aspiration pneumonia during long-term feeding by percutaneous endoscopie gastrostomy: might cisapride play any role? An open pilot study. Support Care Cancer 1994;2:188-190. (Class III)
58. Carter GT, Johnson ER, Bonekat HW, Lieberman JS. Laryngeal diversion in the treatment of intractable aspiration in motor neuron disease. Arch Phys Med Rehabil 1992;73: 680-682. (Class III)
59. Hawthorne M, Gray R, Cottam C. Conservative laryngectomy - an effective treatment for severe aspiration in motor neuron disease. J Laryngol Otol 1987;101:283-285. (Class III)
60. MacDougal G, Wilson JA, Pryde A, Grant R. Analysis of the pharyngoesophageal pressure profile in amyotrophic lateral sclerosis. Otolaryngol Head Neck Surg 1995;112:258-261. (Class II)
61. Aboussouan LS, Khan SU, Meeker DP, Stelmach K, Mitsumoto H. Effect of noninvasive positive-pressure ventilation on survival in amyotrophic lateral sclerosis. Ann Intern Med 1997;127:450-453. (Class II)
62. Barbè F, Quera-Salva MA, de Lattre J, Gajoddos P, Agustii AGN. Long-term effects of nasal intermittent positive-pressure ventilation on pulmonary function and sleep architecture in patients with neuromuscular diseases. Chest 1996; 110:1179-1183. (Class II)
63. Schlamp V, Karg O, Abel A, Schlotter B, Wasner M, Borasio GD. Nicht-invasive intermittierende Selbstbeatmung (ISB) als Palliativmaßnahme bei amyotropher Lateralsklerose [Non-invasive intermittent home mechanical ventilation as a palliative treatment in amyotrophic lateral sclerosis]. Nervenarzt 1998;69:1074-1082. (Class III)
64. Poponick JM, Jacobs I, Supiski G, DiMarco AF. Effect of upper respiratory tract infection in patients with neuromuscular disease. Am J Respir Crit Care Med 1997;156:659-664. (Class III)
65. Fallat RJ, Jewitt B, Bass M, Kamm B, Norris FH Jr. Spirometry in amyotrophic lateral sclerosis. Arch Neurol 1979;36:74-80. (Class III)
66. Rochester DF, Esau SA. Assessment of ventilatory function in patients with neuromuscular disease. Clin Chest Med 1994; 14:751-763. (Class III)
67. Vitacca M, Clini E, Facchetti D, et al. Breathing pattern and respiratory mechanics in patients with amyotrophic lateral sclerosis. Eur Respir J 1997;10:1614-1621. (Class III)
68. Schiffman PL, Belsh JM. Pulmonary function at diagnosis of amyotrophic lateral sclerosis. Rate of deterioration. Chest 1993;103:508-513. (Class III)
69. Griggs RC, Donohoe KM, Utell MJ, Goldblatt D, Moxley RT. Evaluation of pulmonary function in neuromuscular disease. Arch Neurol 1981;38:9-12. (Class III)
70. Kaplan LM, Hollander D. Respiratory dysfunction in amyotrophic lateral sclerosis. Clin Chest Med 1994;15:675-681.
71. Cazzolli PA, Oppenheimer EA. Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation. J Neurol Sci 1996;139(suppl):123-128. (Class III)
72. Bach JR. Amyotrophic lateral sclerosis: predictors for prolongation of life by noninvasive respiratory aids. Arch Phys Med Rehabil 1995;76:828-832. (Class III)
73. Howard RS, Wiles CM, Loh L. Respiratory complications and their management in motor neuron disease. Brain 1989;112: 1155-1170. (Class III)
74. Piper AJ, Sullivan CE. Effects of long-term nocturnal nasal ventilation on spontaneous breathing during sleep in neuromuscular and chest wall disorders. Eur Respir J 1996;9: 1515-1522. (Class II)
75. Pinto AC, Evangelista T, Carvalho M, Alves MA, Sales Luis ML. Respiratory assistance with a non-invasive ventilator (Bipap) in MND/ALS patients: survival rates in controlled trials. J Neurol Sci 1995;129(suppl):19-26. (Class II)
76. Goldblatt D, Greenlaw J. Starting and stopping the ventilator for patients with amyotrophic lateral sclerosis. Neurol Clin 1989;7:789-806. (Class III)
77. Oppenheimer EA. Decision-making in the respiratory care of amyotrophic lateral sclerosis: should home mechanical ventilation be used? Palliat Med 1993;5(suppl 2):49-64. (Class III)
78. Bach JR. Amyotrophic lateral sclerosis. Communication status and survival with ventilatory support. Am J Phys Med Rehabil 1993;72:343-349. (Class III)
79. McDonald ER, Hillel A, Wiedenfeld SA. Evaluation of the psychological status of ventilatory-supported patients with ALS/MND. Palliat Med 1996;10:35-41. (Class II)
80. Moss AH, Oppenheimer EA, Casey P, et al. Patients with amyotrophic lateral sclerosis receiving long-term mechanical ventilation: advance care planning and outcomes. Chest 1996;110:249-255. (Class III)
81. Moss AH, Casey P, Stocking CB, Roos RP, Brooks BR, Siegler M. Home ventilation for amyotrophic lateral sclerosis patients: outcomes, costs, and patient, family and physician attitudes. Neurology 1993;43:438-443. (Class III)
82. Bach JR, Campagnolo DI, Hoeman S. Life satisfaction of individuals with Duchenne muscular dystrophy using long-term mechanical ventilatory support. Am J Phys Med Rehabil 1991;70:129-135. (Class II)
83. American Academy of Neurology Ethics and Humanities Subcommittee. Position statement: certain aspects of the care and management of profoundly and irreversibly paralyzed patients with retained consciousness and cognition. Neurology 1993;43:222-223. (Class III)
84. Bernat JL, Cranford RE, Kittredge FI Jr, Rosenberg RN. Competent patients with advanced states of permanent paralysis have the right to forgo life-sustaining therapy. Neurology 1993;43:224-225. (Class III)
85. Gilligan T, Raffin TA. Withdrawing life support: extubation and prolonged terminal weans are inappropriate. Crit Care Med 1996;24:352-353. (Class III)
86. The American Academy of Neurology Ethics and Humanities Subcommittee. Palliative care in neurology. Neurology 1996;46:870-872. (Class III)
87. Nelson WA, Bernat JL. Decisions to withhold or terminate treatment. Neurol Clin 1989;7:759-773. (Class III)
88. Wilson WC, Smedira NG, Fink C, McDowell JA, Luce JM. Ordering and administration of sedatives and analgesics during the withholding and withdrawal of life support from critically ill patients. JAMA 1992;267:949-953. (Class III)
89. Truog RD, Burns JP. To breathe or not to breathe. J Clin Ethics 1994;5:39-41. (Class III)
90. Campbell ML. Case studies in terminal weaning from mechanical ventilation. Am J Crit Care 1993;2:354-358. (Class III)
91. Campbell ML, Nelson LJ, Hoyt JW. Health Care Ethics Forum 94: perspectives on withholding and withdrawal of life-support. AACN Clin Issues 1994;5:353-359. (Class III)
92. Roelfs RA, Mulder DW. The initial patient interview. In: Mulder DW, ed. The diagnosis and treatment of amyotrophic lateral sclerosis. Boston: Houghton Mifflin Professional Publishers, 1980:129-140. (Class III)
93. Newrick PG, Langton-Hewer R. Pain in motor neuron disease. J Neurol Neurosurg Psychiatry 1985;48:838-840. (Class III)
94. O'Brien T, Kelly M, Sunders C. Motor neuron disease: a hospice perspective. BMJ 1992;304:471-473. (Class III)
95. Oliver D. Ethical issues in palliative care - an overview. Palliat Med 1993;7(suppl 2):15-20. (Class III)
96. Saunders C, Walsh TE, Smith M. Hospice care in motor neuron disease. In: Saunders C, Summers DH, Teller N, eds. Hospice: the living idea. London: Edward Arnold, 1981: 126-147. (Class III)
97. World Health Organization. Cancer pain relief. Report of the WHO expert committee. Technical report series 804. Geneva: World Health Organization, 1990. (Class III)
98. Bruera E, de Stoutz N, Velasco-Leiva A, Schoeller T, Hanson J. Effects of oxygen on dyspnoea in hypoxaemic terminal cancer patients. Lancet 1993;342:13-14. (Class I)
99. Booth S, Kelly MJ, Cox NP, Adams L, Guz A. Does oxygen help dyspnea in patients with cancer? AmJ Respir Grit Care Med 1996;153:1515-1518. (Class III)
100. McIver B, Walsh D, Nelson K. The use of chlorpromazine for symptom control in dying cancer patients. J Pain Symptom Manage 1994;9:341-345. (Class III)
101. Filshie J, Penn K, Ashley S, Davis CL. Acupuncture for the relief of cancer-related breathlessness. Palliat Med 1996;10: 145-150. (Class III)
102. Kane RL, Wales J, Bernstein L, Leibowitz A, Kaplan S. A randomized controlled trial of hospice care. Lancet 1984;1: 890-894. (Class I)
103. Wallston KA, Burger C, Smith RA, Baugher RJ. Comparing the quality of death for hospice and non-hospice cancer patients. Med Care 1988;26:177-182. (Class II)
104. Teno JM, Lynn J, Connors AF Jr, et al. The illusion of end-of-life resource savings with advance directives. SUPPORT Investigators. Study to understand prognoses and preferences for outcomes and risks of treatment. J Am Geriatr Soc 1997;45:513-518. (Class I)
105. Schneiderman LJ, Pearlman RA, Kaplan RM, Anderson JP, Rosenberg EM. Relationship of general advance directives instructions to specific life-sustaining treatment preferences in patients with serious illness. Arch Intern Med 1992;152: 2114-2122. (Class II)
106. SUPPORT principal investigators. A controlled trial to improve care for seriously ill hospitalized patients - the study to understand prognoses and preferences for outcomes and risks of treatment (SUPPORT). JAMA 1995;274:1591-1598. (Class I, II)
107. Reilly BM, Wagner M, Magnussen CR, Ross JH, Papa L, Ash J. Promoting inpatient directives about life-sustaining treatments in a community hospital. Results of a 3-year time-series intervention trial. Arch Intern Med 1995;155:2317-2323. (Class II)
108. Mower WR, Baraff LJ. Advance directives - effect of type of directive on physicians' therapeutic decisions. Arch Intern Med 1993;153:375-381. (Class III)
109. Davidson KW, Hackler C, Caradine DR, McCord RS. Physicians' attitudes on advance directives. JAMA 1989;262: 2415-2419. (Class III)
110. Johnston SC, Pfiefer MP, McNutt R. The discussion about advance directives. Patient and physician opinions regarding when and how it should be conducted. End of Life Study Group. Arch Intern Med 1995;155:1025-1030. (Class III)
111. Silverstein MD, Stocking CB, Antel JP. Amyotrophic lateral sclerosis and life sustaining therapy: a patients' desires for information, participation in decision making and life sustaining therapy. Mayo Clin Proc 1991;66:906-913. (Class III)
112. Voltz R, Borasio G. Palliative therapy in the terminal stage of neurological disease. Neurology 1997;244(suppl 4):S2-S10. (Class III)